S&P 500 slips on report Fed’s Waller leading race to replace Powell; tech shines
In a challenging market environment, Neuraxis (NRXS) stock has recorded a new 52-week low, dipping to $1.38. According to InvestingPro analysis, the company maintains strong gross profit margins of 86.5% and holds more cash than debt on its balance sheet, though it’s currently trading below its Fair Value. This latest price level reflects a significant downturn for the biopharmaceutical company, which has seen its stock value decrease by 47.1% over the past year. Investors have been closely monitoring Neuraxis as it navigates through a series of hurdles, including competitive pressures and a shifting regulatory landscape that have impacted its stock performance. The 52-week low serves as a critical indicator for the company’s stakeholders, marking a period of heightened scrutiny and potential reassessment of investment strategies in the biotech sector. InvestingPro subscribers have access to 10 additional key insights about NRXS, including detailed analysis of its cash burn rate and profitability outlook.
In other recent news, Neuraxis Inc. reported a notable fourth quarter for 2024, with revenues increasing by 43% year-over-year to $761,000. The company’s full-year revenue reached $2.7 million, marking a 9% increase from the previous year. Despite an operating loss of $1.5 million in the fourth quarter, Neuraxis improved its net loss by 73% compared to the same period last year. The company is also targeting cash flow breakeven, anticipating revenue growth through expanded insurance coverage and new product offerings. Neuraxis has expanded its FDA approvals and market reach, which could contribute to future revenue acceleration. Additionally, the company received a Category One CPT code, effective January 1, 2026, which is expected to streamline billing and reimbursement processes. Neuraxis plans to introduce a second-generation IVStim device and has also recently launched the RED device, aiming to further expand its market presence. These developments reflect the company’s efforts to enhance its financial performance and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.